

**Supplemental Table 1. Predictors of treatment completion within each country based on multivariate GLM model accounting for clustering by facility.<sup>1</sup>**

	India (Punjab State only)			Indonesia			Myanmar			Nigeria (Nasarawa State only)			Vietnam		
	% completed treatment	OR (95% CI)	p-value	% completed treatment	OR (95% CI)	p-value	% completed treatment	OR (95% CI)	p-value	% completed treatment	OR (95% CI)	p-value	% completed treatment	OR (95% CI)	
N	79,894/87,522			5,785/7,297			2,003/2,033			120/139			1,749/1,866		
Total %	91.3%			79.3%			98.5%			86.3%			93.7%		
Sex															
Female	96.0%	Ref		78.5%	Ref		98.7%	Ref		85.5%	Ref		94.6%	Ref	
Male	89.2%	<b>0.47 (0.42-0.53)</b>	<b>&lt;0.001</b>	79.9%	0.87 (0.74-1.02)	0.09	98.4%	0.66 (0.35-1.26)	0.21	87.3%	1.31 (0.59-2.93)	0.51	93.6%	0.79 (0.48-1.32)	0.37
Transgender	88.2%	0.56 (0.17-1.90)	0.36	-	-		-			-	-		-		
Unknown	-			0.0%	-		-			-	-		-		
Age															
12-19	83.5%	Ref		85.7%	Ref		100.0% <sup>2</sup>	-		-	-		100.0% <sup>2</sup>	-	-
20-29	86.4%	<b>1.18 (1.02-1.37)</b>	<b>0.02</b>	76.2%	0.77 (0.32-1.89)	0.58	97.5%	Ref		100.0% <sup>2</sup>	-		91.7%	Ref	
30-39	91.7%	<b>1.81 (1.56-2.11)</b>	<b>&lt;0.001</b>	84.2%	0.83 (0.29-2.34)	0.72	98.9%	2.43 (0.23-25.62)	0.46	83.3% <sup>2</sup>	Ref		93.9%	1.32 (0.88-1.96)	0.17
40-49	94.8%	<b>2.77 (2.30-3.33)</b>	<b>&lt;0.001</b>	80.8%	1.04 (0.38-2.87)	0.94	98.6%	2.51 (0.30-20.72)	0.39	83.3%	1.12 (0.15-8.57)	0.91	93.9%	<b>1.46 (1.00-2.13)</b>	<b>0.05</b>
50-59	94.5%	<b>2.77 (2.41-3.18)</b>	<b>&lt;0.001</b>	76.4%	0.89 (0.35-2.29)	0.81	99.1%	4.79 (0.74-30.95)	0.10	90.2%	2.27 (0.62-8.30)	0.22	94.3%	<b>1.60 (1.11-2.29)</b>	<b>0.01</b>
60-69	93.1%	<b>2.23 (1.86-2.67)</b>	<b>&lt;0.001</b>	74.6%	0.85 (0.33-2.16)	0.73	97.1%	1.78 (0.33-9.66)	0.50	80.0%	0.87 (0.20-3.86)	0.86	92.4%	1.06 (0.70-1.59)	0.79
70+	90.0%	<b>1.57 (1.31-1.88)</b>	<b>&lt;0.001</b>	72.4%	0.70 (0.25-1.97)	0.50	99.3%	<b>8.06 (1.35-48.10)</b>	<b>0.02</b>	83.3%	1.08 (0.09-12.48)	0.95	93.2%	1.26 (0.72-2.20)	0.41
Missing	91.1%	<b>2.00 (1.00-3.98)</b>	<b>0.05</b>	76.9%	0.58 (0.17-1.99)	0.39	100.0% <sup>2</sup>	-	-	-			-		
Family history of HCV															
Yes	84.1%	<b>0.69 (0.55-0.86)</b>	<b>0.001</b>	-	-	-	99.5%	2.57 (0.71-9.37)	0.15	100.0% <sup>2</sup>			-	-	-

None Reported	91.3%	Ref		-	-	-	98.4%	Ref		86.2%		-	-	-
History of injecting drugs														
Yes	76.8%	<b>0.75 (0.57-0.98)</b>	<b>0.03</b>	88.4%	<b>1.79 (1.32-2.41)</b>	<b>&lt;0.001</b>	99.6%	4.70 (0.73-30.19)	0.10	-		93.8%	0.92 (0.61-1.37)	0.67
None reported	92.0%	Ref		76.8%	Ref		98.4%	Ref		86.3%		93.7%	Ref	
Known HIV co-infection														
Yes	75.3%	-	-	84.7%	-	-	98.8%	-	-	100.0% <sub>2</sub>		94.8%	-	-
No	91.6%	-	-	77.7%	-	-	98.4%	-	-	86.0%		93.2%	-	-
Known HBV co-infection														
Yes	33.3% <sub>2</sub>	-	-	-	-	-	100.0%	-	-	100.0%		93.1%	-	-
No	91.3%	-	-	-	-	-	98.5%	-	-	85.3%		93.8%	-	-
Cirrhosis														
Compensated	89.8%	1.03 (0.87-1.22)	0.73	-	-	-	98.3%	<b>2.98 (1.14-7.84)</b>	<b>0.03</b>	-		92.1%	<b>0.61 (0.43-0.87)</b>	<b>0.01</b>
Decompensated	79.5%	<b>0.46 (0.34-0.62)</b>	<b>&lt;0.001</b>	-	-	-	99.4%	9.85 (0.51-188.88)	0.13	-		93.2%	<b>0.62 (0.49-0.78)</b>	<b>&lt;0.001</b>
Cirrhotic (no additional information)	88.4%	1.06 (0.81-1.39)	0.66	69.6%	0.92 (0.43-1.98)	0.83	-	-	-	100.0% <sub>2</sub>		-	-	-
Non-cirrhotic	91.7%	Ref		85.2%	Ref		98.5%	Ref		85.6%		94.8%	Ref	
Unknown	-	-	-	50% <sup>2</sup>	<b>0.20 (0.06-0.68)</b>	<b>0.01</b>		-	-				-	-
Treatment regimen														
SOF/DCV	91.6%	Ref		78.9%	Ref		98.5%	-	-	86.3%		94.1%	Ref	
SOF/DCV+RBV	64.2%	<b>0.17 (0.05-0.66)</b>	<b>0.01</b>	90.4%	1.41 (0.76-2.63)	0.28	-	-	-	-		93.1%	1.05 (0.80-1.37)	0.74
SOF/VEL	89.8%	0.99 (0.79-1.24)	0.94	-	-	-	-	-	-	-		-	-	-
SOF/VEL+RBV	90.3%	0.91 (0.71-1.17)	0.47	-	-	-	-	-	-	-		-	-	-
Other	85.2%	<b>0.34 (0.13-0.88)</b>	<b>0.03</b>	80.0%	0.92 (0.55-1.56)	0.76	-	-	-	-		-	-	-
Treatment duration														
12 weeks	91.8%	Ref		85.5%	Ref		99.3%	Ref		85.6%		93.9%	Ref	

24 weeks	86.5%	<b>0.34 (0.27-0.44)</b>	<b>&lt;0.001</b>	68.9%	<b>0.38 (0.18-0.83)</b>	<b>0.02</b>	96.9%	<b>0.10 (0.02-0.40)</b>	<b>0.001</b>	100.0% <sup>2</sup>			91.8%	0.93 (0.75-1.17)	0.55
Other	97.2%	2.29 (0.84-6.25)	0.11	-	-	-	-	-	-	-			100.0% <sup>2</sup>	-	-
Year of treatment initiation		<b>0.65 (0.60-0.71)</b>	<b>&lt;0.001</b>		<b>0.69 (0.60-0.80)</b>	<b>&lt;0.001</b>		<b>0.41 (0.18-0.94)</b>	<b>0.04</b>		<b>0.47 (0.37-0.59)</b>	<b>&lt;0.001</b>		<b>0.53 (0.35-0.80)</b>	<b>0.003</b>
2016	97.1%			-			-			0.0% <sup>2</sup>			-		
2017	94.0%			82.8%			98.7%			100.0%			95.8%		
2018	92.3%			86.0%			97.7%			91.7%			92.4%		
2019	86.9%			84.6%			-			79.4%			100.0% <sup>2</sup>		
2020	83.6%			76.9%			-			-			-		
2021	80.1%			66.2%			-			-			-		
2022	-			0.0%			-			-			-		

<sup>1</sup>Patients who died were excluded from this analysis, as the data did not consistently indicate the timing of death (pre- or post-treatment completion).

<sup>2</sup>Sample size was <10 people in this category.

**Supplemental Table 2. Predictors of cure (confirmed by SVR12) within each country based on multivariate GLM model accounting for clustering by facility.<sup>1</sup>**

	India (Punjab State only)			Indonesia			Myanmar			Nigeria (Nasarawa State only) <sup>4</sup>			Vietnam		
	% cured	OR (95% CI)	P	% cured	OR (95% CI)	P	% cured	OR (95% CI)	P	% cured	OR (95% CI)	P	% cured	OR (95% CI)	P
N	58,902/63,746			2,576/2,667			1,648/1,826			36/39			1,143/1,151		
Total %	92.4%			96.6%			90.3%			92.3%			99.3%		
Sex															
Female	95.0%	Ref		96.5%	Ref		92.2%	Ref		92.9%	-	-	98.5%	Ref	
Male	91.0%	<b>0.61 (0.44-0.85)</b>	<b>0.004</b>	96.6%	1.07 (0.68-1.70)	0.77	88.4%	<b>0.62 (0.46-0.84)</b>	<b>0.002</b>	90.9%	-	-	99.5%	<b>3.63 (1.23-10.72)</b>	<b>0.02</b>
Transgender	100.0%	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Age															
12-19	84.5% <sup>2</sup>	Ref		100.0%	-	-	50.0% <sup>3</sup>	Ref		-	-	-	100.0% <sup>3</sup>	-	-
20-29	87.5%	<b>1.26 (1.04-1.52)</b>	<b>0.02</b>	94.6%	Ref		93.9%	<b>16.89 (3.09-92.49)</b>	<b>0.001</b>	100.0% <sup>3</sup>	-	-	100.0%	-	-
30-39	93.4%	<b>2.39 (1.91-3.00)</b>	<b>&lt;0.001</b>	97.7%	<b>2.35 (1.17-4.71)</b>	<b>0.02</b>	93.0%	<b>14.36 (1.27-162.83)</b>	<b>0.03</b>	90.0%	-	-	99.0%	Ref	
40-49	94.4%	<b>2.77 (1.96-3.92)</b>	<b>&lt;0.001</b>	95.2%	1.10 (0.48-2.53)	0.82	89.0%	8.82 (0.69-112.21)	0.09	100.0% <sup>3</sup>	-	-	99.5%	<b>2.09 (1.04-4.17)</b>	<b>0.04</b>

50-59	94.4%	<b>2.75</b> (1.95-3.8)	<b>&lt;0.001</b>	95.9%	1.25 (0.55-2.88)	0.59	89.5%	9.29 (0.63-137.01)	0.10	100.0%	-	-	100.0%	-	-
60-69	93.7%	<b>2.44</b> (1.70-3.49)	<b>&lt;0.001</b>	97.6%	2.12 (0.95-4.75)	0.07	91.2%	11.04 (0.88-138.51)	0.06	66.7% <sup>3</sup>	-	-	100.0%	-	-
70+	94.3%	<b>2.78</b> (2.02-3.82)	<b>&lt;0.001</b>	98.1%	2.74 (0.93-8.13)	0.07	90.2%	9.90 (0.83-118.60)	0.07	100.0% <sup>3</sup>	-	-	96.0%	<b>0.47</b> (0.24-0.93)	<b>0.03</b>
Missing	93.6%	<b>2.49</b> (1.21-5.12)	<b>0.01</b>	95.5%	1.16 (0.20-6.71)	0.87	-	-	-	-	-	-	-	-	-
Family history of HCV															
Yes	97.9%	3.83 (2.59-5.67)	<b>&lt;0.001</b>	-	-	-	91.4%	1.05 (0.58-1.91)	0.88	100.0% <sup>3</sup>	-	-	-	-	-
None Reported	92.4%	Ref		-	-	-	90.1%	Ref		92.1%	-	-	-	-	-
History of injecting drugs															
Yes	84.6%			96.0%			86.1%			92.3%			99.6%		
None reported	92.6%			96.8%			90.8%			-			99.1%		
Known HIV co-infection															
Yes	83.2%			97.0%			89.7%			100.0% <sup>3</sup>			99.6%		
No	92.5%			96.4%			90.6%			92.1%			99.1%		
Known HBV co-infection															
Yes	-	-	-	-	-	-	92.1%	1.38 (0.40-4.76)	0.61	66.7% <sup>3</sup>	-	-	98.2%	<b>0.22</b> (0.05-0.93)	<b>0.04</b>
No	92.4%	-	-	-	-	-	90.2%	Ref		94.4%	-	-	99.4%	Ref	
Cirrhosis															
Compensated	93.0%	0.74 (0.50-1.08)	0.12	-	-	-	90.0%	0.88 (0.65-1.20)	0.42	-	-	-	99.2%	1.81 (0.57-5.78)	0.32
Decompensated	93.7%	0.82 (0.55-1.23)	0.34	-	-	-	86.4%	<b>0.62</b> (0.46-0.84)	<b>0.002</b>	-	-	-	100.0%	-	-
Cirrhotic (no additional information)															
Non-cirrhotic	91.5%	<b>0.74</b> (0.54-1.00)	<b>0.05</b>	97.0%	1.22 (0.68-2.17)	0.51	-	-	-	100.0% <sup>3</sup>	-	-	-	-	-
Unknown	92.4%	Ref		96.4%	Ref		90.7%	-	-	91.7%	-	-	99.3%	Ref	
Treatment regimen															
SOF/DCV	92.1%	Ref		96.5%	Ref		90.3%	-	-	92.3%	-	-	99.5%	Ref	

SOF/DCV+RBV	81.0%	0.37 (0.10- 1.36)	0.14	97.7%	1.37 (0.37- 5.00)	0.64	-	-	-	-	-	-	99.0%	0.31 (0.02- 3.96)	0.37
SOF/VEL	91.7%	0.96 (0.69- 1.34)	0.82	-	-	-	-	-	-	-	-	-	-	-	-
SOF/VEL+RBV	94.4%	<b>1.45</b> <b>(1.27- 1.65)</b>	<b>&lt;0.001</b>	-	-	-	-	-	-	-	-	-	-	-	-
Other	86.4%	-	-	96.7%	1.13 (0.57- 2.24)	0.72	-	-	-	-	-	-	-	-	-
Treatment duration															
12 weeks	92.2%	-	-	96.4%	-	-	90.1%	-	-	91.7%	-	-	99.3%	-	-
24 weeks	93.9%	-	-	97.0%	-	-	90.5%	-	-	100.0% <sup>3</sup>	-	-	100.0%	-	-
Other	94.2%	-	-	-	-	-	-	-	-	-	-	-	100.0% <sup>3</sup>	-	-
Year of treatment initiation															
2016	94.2%	-	-	-	-	-	-	-	-	-	-	-	-	-	-
2017	91.4%	-	-	97.8%	-	-	90.1%	-	-	100.0% <sup>3</sup>	-	-	99.1%	-	-
2018	93.4%	-	-	95.6%	-	-	91.2%	-	-	87.5%	-	-	99.5%	-	-
2019	90.8%	-	-	96.7%	-	-	-	-	-	100.0% <sup>3</sup>	-	-	100.0% <sup>3</sup>	-	-
2020	90.8%	-	-	96.7%	-	-	-	-	-	-	-	-	-	-	-
2021	76.9%	-	-	96.1%	-	-	-	-	-	-	-	-	-	-	-

<sup>1</sup>Among those who completed SVR12 testing.

<sup>2</sup>This group demonstrated statistically significant differences from other groups (combined) in a chi-square analyses accounting for clustering by health facility.

<sup>3</sup>Sample size was <10 people in this category.

<sup>4</sup>Country not modeled due to small sample sizes.